The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma: A gynecologic oncology group study

Cancer

Volumn 115, Issue 5, 2009, Pages 1028-1035

  Zorn, Kristin K ^a,b   Tian, Chunqiao ^c   McGuire, William P ^d   Hoskins, William J ^e   Markman, Maurie ^f   Muggia, Franco M ^g   Rose, Peter G ^h   Ozols, Robert F ⁱ   Spriggs, David ^e   Armstrong, Deborah K ^j  

^a University of Pittsburgh Medical Center ^*  (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d Franklin Square Hospital Center   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^h LERNER RESEARCH INSTITUTE   (United States)

ⁱ FOX CHASE CANCER CENTER   (United States)

^j JOHNS HOPKINS UNIVERSITY   (United States)

more..

Author keywords

CA 125 tumor marker; Epithelial ovarian cancer; Gynecologic Oncology Group; Progression free survival

Indexed keywords

CA 125 ANTIGEN; CISPLATIN; PACLITAXEL;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CANCER SURGERY; CYTOREDUCTIVE SURGERY; FEMALE; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY;

EID: 61449216113     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24084     Document Type: Article

References (16)

1. Bast RC Jr, Feeney M, Lazarus H, et al. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981;68:1331-1337.
2. Yin BW, Lloyd KO. Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J Biol Chem. 2001;20:27371-27375.
3. Bast RC Jr, Klug TL, St John E, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983:309: 883-887.
4. Jacobs I, Bast RJ Jr. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod. 1989;4:1-12.
5. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334:1-6.
6. Markman M, Bundy B, Alberts D, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19:1001-1007.
7. Muggia FM, Braly PS, Brady MF, et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2000;18:106-115.
8. Rose PG, Nerenstone S, Brady MF, et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med. 2004;351:2489-2497.
9. Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003;21:3194-3200.
10. Spriggs D, Brady MF, Rubin SC, et al. A. phase III randomized trial of cisplatin and paclitaxel administered by either 24 hour or 96 hour infusion in patients with selected stage III or stage IV epithelial ovarian cancer [abstract]. Proc Am Soc Clin Oncol. 2004;23:449. Abstract 5004.
11. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34-43.
12. Hosmer D, Lemeshow S. Applied Survival Analysis: Regression Modeling of Time to Event Data. New York: John Wiley & Sons; 1999.
13. Talbot RW, Jacobsen DJ, Nagorney DM, et al. Temporary elevation after abdominal surgical treatment for benign disease and cancer. Surg Gynecol Obstet. 1989;168:407-412.
14. Markman M, Federico M, Liu PY, et al. Significance of early changes in the serum. CA-125 antigen level on overall survival in advanced ovarian cancer. Gynecol Oncol. 2006;103:195-198.
15. Winter ME 3rd, Maxwell GL, Tian C, et al. Gynecologic Oncology Study Group. Prognostic factors for stage III epithelial ovarian cancer: a. Gynecologic Oncology Group smdy. J Clin Oncol. 2007;24:3621-3627.
16. Chan JK, Tian C, Monk BJ, et al. Gynecologic Oncology Group. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study. Cancer. 2008;112:2202-2210.